Abstract: The technologies described herein are generally directed to provisioning services from a network. For example, a method described herein can include facilitating receiving a provisioning request for a network provisioning task. Further, the method can include, based on the network provisioning task, selecting a logical provisioning template to facilitate a performance of the network provisioning task. Further, based on the logical provisioning template, the method can include identifying a programming object comprising logical commands for the performance of the network provisioning task. The method can include executing the logical commands of the programming object to control service implementation equipment to perform the network provisioning task.

Abstract: Devices, computer-readable media, and methods for reclaiming and reallocating stranded Internet Protocol assets are disclosed. In one example, a method includes acquiring a plurality of reports detailing the usage and availability of a packet-switched network, classifying, based on the plurality of reports, a plurality of hosts in the packet-switched network, identifying, based on the classifying, a first host of the plurality of hosts from which to reclaim an Internet Protocol asset, and reclaiming the Internet Protocol asset from the first host and reassigning the Internet Protocol asset to a pool of available Internet Protocol assets.

Abstract: Aspects of the subject disclosure may include, for example, receiving instructions to validate a configuration associated with an application under test, the instructions identifying the application under test that exists in a first particular software environment that is selected from among a plurality of software environments; receiving dependency data, the dependency data identifying a dependency application that exists in a second particular software environment that is selected from among the plurality of software environments; performing a first process to determine whether the application under test that exists in the first particular software environment can be instantiated as a first running application, the first process resulting in a first determination; responsive to the first determination being that the application under test that exists in the first particular software environment can be instantiated as the first running application, automatically performing with no user interaction a second p

Abstract: The technologies described herein are generally directed to provisioning services from a network. For example, a method described herein can include facilitating receiving a provisioning request for a network provisioning task. Further, the method can include, based on the network provisioning task, selecting a logical provisioning template to facilitate a performance of the network provisioning task. Further, based on the logical provisioning template, the method can include identifying a programming object comprising logical commands for the performance of the network provisioning task. The method can include, executing the logical commands of the programming object to control service implementation equipment to perform the network provisioning task.

Abstract: Aspects of the subject disclosure may include, for example, receiving instructions to validate a configuration associated with an application under test, the instructions identifying the application under test that exists in a first particular software environment that is selected from among a plurality of software environments; receiving dependency data, the dependency data identifying a dependency application that exists in a second particular software environment that is selected from among the plurality of software environments; performing a first process to determine whether the application under test that exists in the first particular software environment can be instantiated as a first running application, the first process resulting in a first determination; responsive to the first determination being that the application under test that exists in the first particular software environment can be instantiated as the first running application, automatically performing with no user interaction a second p

Abstract: The technologies described herein are generally directed to provisioning services from a network. For example, a method described herein can include facilitating receiving a provisioning request for a network provisioning task. Further, the method can include, based on the network provisioning task, selecting a logical provisioning template to facilitate a performance of the network provisioning task. Further, based on the logical provisioning template, the method can include identifying a programming object comprising logical commands for the performance of the network provisioning task. The method can include, executing the logical commands of the programming object to control service implementation equipment to perform the network provisioning task.

Abstract: For systems that can include, but are not limited to telecommunications, content distribution, and internetworking, the technologies described herein are generally directed to deploying network services, e.g., for large inventories of network equipment, complex deployments, and different processes being handled by isolated and difficult to modify legacy systems. For example, a method described herein can include receiving, by operations support equipment comprising a processor, a provisioning request for a network provisioning task. The method can further include, based on the network provisioning task, selecting, by the operations support equipment, a logical provisioning model to facilitate processing the provisioning request. Further, the network can include, based on the logical provisioning model, identifying, by the operations support equipment, an infrastructure engine to provision network equipment corresponding to the network provisioning task.

Abstract: Aspects of the subject disclosure may include, for example, receiving instructions to validate a configuration associated with an application under test, the instructions identifying the application under test that exists in a first particular software environment that is selected from among a plurality of software environments; receiving dependency data, the dependency data identifying a dependency application that exists in a second particular software environment that is selected from among the plurality of software environments; performing a first process to determine whether the application under test that exists in the first particular software environment can be instantiated as a first running application, the first process resulting in a first determination; responsive to the first determination being that the application under test that exists in the first particular software environment can be instantiated as the first running application, automatically performing with no user interaction a second p

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.

Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).